Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lumos Diagnostics HoldingsASX:LDX 20 Equity-to-Asset is 0.25 as of Dec. 2025, which is 36% below its 10-year median of 0.39. GuruFocus rates ASX:LDX with a GF Score™ of 20/100 and a GF Value™ of A$0.03 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Lumos Diagnostics Holdings ranks worse than 86.74% on this metric.
The historical rank and industry rank for Lumos Diagnostics Holdings's Equity-to-Asset or its related term are showing as below:
ASX:LDX'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.25 Med: 0.39 Max: 0.86
Current: 0.25
During the past 4 years, the highest Equity to Asset Ratio of Lumos Diagnostics Holdings was 0.86. The lowest was 0.25. And the median was 0.39.
ASX:LDX's Equity-to-Asset is ranked worse than 86.74% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 0.645
vs ASX:LDX: 0.25
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Lumos Diagnostics Holdings Equity-to-Asset Related Terms
Lumos Diagnostics Holdings Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:LDX vs ABT, SYK, MDT: Equity-to-Asset Comparison
For the Medical Devices subindustry, Lumos Diagnostics Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lumos Diagnostics Holdings Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lumos Diagnostics Holdings's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Lumos Diagnostics Holdings's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Lumos Diagnostics Holdings's Equity to Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lumos Diagnostics Holdings (ASX:LDX) has a Equity-to-Asset of 0.25 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Lumos Diagnostics Holdings and its competitors. This is 36% below median its historical median of 0.39. Over the past decade, Lumos Diagnostics Holdings' Equity-to-Asset has ranged from 0.25 to 0.86. According to the industry distribution chart, Lumos Diagnostics Holdings ranks #739 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 86.7%.
Is Lumos Diagnostics Holdings' Equity-to-Asset too high?
Lumos Diagnostics Holdings' current Equity-to-Asset of 0.25 is 36% below median its 10-year median of 0.39. Over the past 10 years, this metric has ranged from a low of 0.25 to a high of 0.86. The Medical Devices & Instruments industry median Equity-to-Asset is 0.65. Lumos Diagnostics Holdings' value of 0.25 is 61.2% below this industry median. Based on the distribution chart, Lumos Diagnostics Holdings ranks #739 out of 852 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Lumos Diagnostics Holdings has a GF Score™ of 20/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lumos Diagnostics Holdings' Equity-to-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Lumos Diagnostics Holdings ranks #739 out of 852 companies for Equity-to-Asset. This places Lumos Diagnostics Holdings in the lower half of its industry. The industry median Equity-to-Asset is 0.65. Lumos Diagnostics Holdings' value of 0.25 is 61.2% below this benchmark. Historically, Lumos Diagnostics Holdings' own Equity-to-Asset has ranged from 0.25 to 0.86 over the past decade. While the company's 10-year median is 0.39 vs. the industry median of 0.65, Lumos Diagnostics Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.65, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lumos Diagnostics Holdings's current Equity-to-Asset of 0.25 is 61.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Lumos Diagnostics Holdings and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lumos Diagnostics Holdings's current Equity-to-Asset is 0.25, which is 36% below median its own 10-year median of 0.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumos Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lumos Diagnostics Holdings (ASX:LDX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.13 — trading 316.7% above its estimated fair value. The current Equity-to-Asset is 0.25, which is 36% below median its 10-year median of 0.39 and 61.2% below the Medical Devices & Instruments industry median of 0.65. Lumos Diagnostics Holdings' overall GF Score™ is 20/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Lumos Diagnostics Holdings (ASX:LDX), the current Equity-to-Asset is 0.25 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lumos Diagnostics Holdings (ASX:LDX) Overvalued in 2026?
Based on GuruFocus' analysis, Lumos Diagnostics Holdings stock appears to be overvalued.
The current stock price of A$0.13 is trading 316.7% above its estimated GF Value™ of A$0.03.
GuruFocus considers Lumos Diagnostics Holdings to be Significantly Overvalued.
Key valuation signals for ASX:LDX:
Equity-to-Asset: 0.25 (36% below median its 10-year median of 0.39)
GF Value™: A$0.03 vs. price of A$0.13 (316.7% above fair value)
Industry Position: 61.2% below the Medical Devices & Instruments median (#739 of 852)
No single metric tells the full story. See the ASX:LDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services. The Company operates in two geographical regions, the United States and Australia and the majority of revenue is generated from the United States.
20GF Score
Get the complete analysis for ASX:LDX
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:LDX has been successfully added to your 
